US20040143207A1 - Apparatus usable in haemofiltration treatment - Google Patents

Apparatus usable in haemofiltration treatment Download PDF

Info

Publication number
US20040143207A1
US20040143207A1 US10/699,098 US69909803A US2004143207A1 US 20040143207 A1 US20040143207 A1 US 20040143207A1 US 69909803 A US69909803 A US 69909803A US 2004143207 A1 US2004143207 A1 US 2004143207A1
Authority
US
United States
Prior art keywords
blood
patient
pump
oxygenating device
oxygenating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/699,098
Inventor
Florenziano Torre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Freeview Ventures LLC
Original Assignee
Freeview Ventures LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32088997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040143207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Freeview Ventures LLC filed Critical Freeview Ventures LLC
Assigned to FREEVIEW VENTURES LLC reassignment FREEVIEW VENTURES LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DELLA TORRE, FLORENZIANO
Publication of US20040143207A1 publication Critical patent/US20040143207A1/en
Priority to US12/043,696 priority Critical patent/US7942842B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1698—Blood oxygenators with or without heat-exchangers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3626—Gas bubble detectors

Definitions

  • the present invention relates to an apparatus usable in CRRT (Continuous Renal Replacement Therapy) treatment.
  • CRRT Continuous Renal Replacement Therapy
  • haemodialysis haemofiltration
  • ultrafiltration all of which provide for removing waste products from the patient. That is, the patient's blood is fed through filters or membranes to eliminate the waste substances in it, and is then fed back to the patient.
  • CAVH Continuous ArterioVenous Haemofiltration
  • CVVH Continuous VenoVenous Haemofiltration
  • CRRT CRRT
  • a CRRT machine comprises a central unit connected at the input and output to the patient, e.g. by means of one or more catheters inserted inside corresponding blood vessels, to continuously withdraw the blood for treatment and feed back the treated blood.
  • the central unit of a CRRT machine normally comprises a blood pump, blood heating and processing means, such as, heparin adding means, means for feeding refill liquid into the blood, and a haemofilter.
  • the blood withdrawn continuously from the patient is thus pumped by the blood pump along the machine circuit, heparin and appropriately heated refill liquid is added, and the blood is then filtered before being fed back to the patient.
  • the advantages of the apparatus according to the present invention substantially lie in greatly improving “decapneisation”, i.e. in greatly reducing the CO 2 values of the blood.
  • reducing FiO 2 from 100 to 70% has been found to increase O 2 saturation of the patient from 92 to 100%. This is extremely important, in that the poor capacity of the lung to exchange O 2 constitutes a serious complication in many patients.
  • Another advantage lies in the principle of the present invention being applicable to existing machines, which can be altered to achieve more complete, more effective performance.
  • the characteristics of an apparatus in accordance with the invention remain unchanged with very little maintenance.
  • FIG. 1 shows, schematically and not to scale, one possible embodiment of a CRRT apparatus in accordance with the present invention.
  • Number 1 in FIG. 1 indicates as a whole a CRRT apparatus in accordance with the present invention.
  • Apparatus 1 is connected at the input to a patient P by a first conduit 9 , which may be defined, for example, by a Horizon Medical Product DLC600 KC 11.5 Fr or DLC 800 KC femoral catheter.
  • a first conduit 9 which may be defined, for example, by a Horizon Medical Product DLC600 KC 11.5 Fr or DLC 800 KC femoral catheter.
  • Other means may, of course be used to connect the apparatus to the patient, and data relative to other component parts described herein is also provided purely by way of non-limiting examples.
  • Catheter 9 is connected to a conduit 90 , which is fitted with and acted on downstream by a blood pump 3 ; a gauge 20 is also provided to measure the intake arterial pressure of the patient.
  • the successive portions of the path along which the blood flows are defined by conduit portions 91 , 92 , 93 , 94 and 95 .
  • Pump 3 pumps the blood downstream (in the direction shown by the arrows) to a connecting member 4 , after first adding heparin by means of a conduit 50 connected to conduit 91 and to a heparin tank (syringe) 5 .
  • a conduit 60 is connected to the input of connecting member 4 to supply, by means of a pump 61 , a refill liquid or infusion contained in a tank 6 and heated by heating means 62 .
  • a gauge 40 is provided at connecting member 4 to measure the pressure at that point along the path.
  • conduit portion 92 Downstream from connecting member 4 , conduit portion 92 is connected to an oxygenating device 7 or “decapneisator”, which may be a Jostra Polystan mycro or Jostra Safe mycro neonatal type, and which is connected by a conduit 77 to an oxygen tank 78 , and is fitted inside with an oxygenating membrane 71 .
  • Oxygenating device 7 provides for supplying oxygen to eliminate CO 2 from the blood; for which purpose, CO 2 is eliminated through an outlet 70 of device 7 and sent to measuring means not shown.
  • conduit portion 93 Downstream from “decapneisator” 7 , conduit portion 93 is connected to a blood filter or haemofilter 8 having an output connected to a conduit 80 for discharging ultrafiltrate into a collecting tank 81 .
  • Conduit 80 is fitted with control means 82 , which may be defined, for example, by a detector for detecting blood loss in the ultrafiltrate, and which acts directly on conduit 80 .
  • Blood filter 8 may be a currently marketed type, such as a MEDICA company MEDISULFONE D200 haemofilter.
  • Apparatus 1 according to the present invention advantageously does not employ an ultrafiltrate pump, in that, using oxygenating device 7 , ultrafiltration takes place naturally, in a more physiologically correct manner.
  • conduit portion 94 Downstream from filter 8 , conduit portion 94 is connected to a member 49 defined by a venous vessel and having a gauge 48 for measuring the pressure of the return blood to the patient.
  • conduit portion 95 Downstream from member 49 , conduit portion 95 —which is fitted with an air detector 47 to prevent emboli (e.g. a UABD ultrasonic air bubble detector)—is connected to a return catheter 9 ′ for feeding the blood back to patient P.
  • emboli e.g. a UABD ultrasonic air bubble detector
  • an apparatus in accordance with the present invention comprises a CRRT machine, and an oxygenating device or “decapneisator”.
  • the CRRT machine may be an Equasmart Medica equipped with appropriate connecting tubes, catheters, connections, etc.
  • the apparatus is advantageous in all cases in which the oxygen concentration of the blood requires supplementing, and especially in eliminating CO 2 in patients in which correct substitute respiration therapy is difficult to apply.
  • the apparatus is connected to the patient undergoing CVVH treatment, and a patient weight loss is set as required. For example, a total weight loss of 2400 g and an hourly loss of 100 g may be programmed. These two parameters determine a treatment time of 24 hours. Administration of an anticoagulant equal to 1.5 times the blood coagulation time may be set; in which case, a pump flow rate (QB) of 280-300 ml/min and an oxygen flow rate (QO 2 ) of 500 ml/min will be programmed.
  • QB pump flow rate
  • QO 2 oxygen flow rate
  • the patient is connected to a CRRT machine, using an oxygenating device located and acting upstream from the blood filter and downstream from the blood pump.
  • This location of the oxygenating device is particularly important. In fact, it means the oxygenating membranes of the oxygenating device operate without the intake (negative) pressure along the portion upstream from the blood pump, and also without the blood concentration characteristic of the venous portion, which could eventually impair their efficiency.
  • a weight loss i.e. the quantity of liquid to be drained
  • An anticoagulant infusion in line with standard CRRT protocols will therefore be provided, with a blood flow rate (QB) of over 300 ml/min, and an oxygen flow rate (QO 2 ) higher than QB. It is important to continuously monitor both coagulation time, which must be kept constantly at one and a half times normal, and oxygen saturation, haematocrit, blood volume values, etc.
  • a CRITE-LINE or similar apparatus may be used.

Abstract

The invention relates to an apparatus for CRRT therapy of the type performable using a haemofiltration machine, having connecting means from and to respective blood vessels of a patient, blood processing means including a pump, means for adding drugs or other therapeutic substances, means for feeding refill liquid into the blood, and blood filtration means, cascade-connected to one another by relative conduits; the apparatus also having an oxygenating device.

Description

  • The present invention relates to an apparatus usable in CRRT (Continuous Renal Replacement Therapy) treatment. [0001]
    • BACKGROUND OF THE INVENTION
  • As is known, for various reasons, it may prove necessary to supplement or replace the renal function of patients to remove waste liquids and soluble substances, such as substances administered to the patient and/or waste substances contained in the blood as a result of pathology, surgery, etc. [0002]
  • Various procedures are employed for this purpose, including haemodialysis, haemofiltration, and ultrafiltration, all of which provide for removing waste products from the patient. That is, the patient's blood is fed through filters or membranes to eliminate the waste substances in it, and is then fed back to the patient. [0003]
  • For patients in grave conditions, procedures include Continuous ArterioVenous Haemofiltration (CAVH), Continuous VenoVenous Haemofiltration (CVVH), or, in general, CRRT as defined above. In this type of procedure, the patient is connected permanently to the haemofiltration machine for a prolonged period of time. [0004]
  • Examples of known CRRT machines are described in U.S. Pat. No. 5,211,849 and U.S. Pat. No. 6,349,170. That is, a CRRT machine comprises a central unit connected at the input and output to the patient, e.g. by means of one or more catheters inserted inside corresponding blood vessels, to continuously withdraw the blood for treatment and feed back the treated blood. The central unit of a CRRT machine normally comprises a blood pump, blood heating and processing means, such as, heparin adding means, means for feeding refill liquid into the blood, and a haemofilter. The blood withdrawn continuously from the patient is thus pumped by the blood pump along the machine circuit, heparin and appropriately heated refill liquid is added, and the blood is then filtered before being fed back to the patient. [0005]
  • A major drawback of currently used CRRT systems is their slow speed in relation to patient requirements. [0006]
  • Another drawback of known CRRT systems is the compulsory use of a pump for the ultrafiltrate, which is less tolerable by chronic, haemodynamically unstable patients whose refill capacity is always unknown. [0007]
    • SUMMARY OF THE INVENTION
  • It is a main object of the present invention to eliminate the aforementioned drawbacks. [0008]
  • According to the present invention, there is provided a CRRT apparatus as claimed in [0009] claim 1 and the dependent claims.
  • The advantages of the apparatus according to the present invention substantially lie in greatly improving “decapneisation”, i.e. in greatly reducing the CO[0010] 2 values of the blood. By way of example, reducing FiO2 from 100 to 70% has been found to increase O2 saturation of the patient from 92 to 100%. This is extremely important, in that the poor capacity of the lung to exchange O2 constitutes a serious complication in many patients. Another advantage lies in the principle of the present invention being applicable to existing machines, which can be altered to achieve more complete, more effective performance. Moreover, the characteristics of an apparatus in accordance with the invention remain unchanged with very little maintenance.
    •  BRIEF DESCRIPTION OF THE DRAWINGS
  • A non-limiting embodiment of the present invention will be described by way of example with reference to the accompanying drawing, in which: [0011]
  • FIG. 1 shows, schematically and not to scale, one possible embodiment of a CRRT apparatus in accordance with the present invention.[0012]
    • DETAILED DESCRIPTION OF THE INVENTION
  • [0013] Number 1 in FIG. 1 indicates as a whole a CRRT apparatus in accordance with the present invention.
  • [0014] Apparatus 1 is connected at the input to a patient P by a first conduit 9, which may be defined, for example, by a Horizon Medical Product DLC600 KC 11.5 Fr or DLC 800 KC femoral catheter. Other means may, of course be used to connect the apparatus to the patient, and data relative to other component parts described herein is also provided purely by way of non-limiting examples.
  • [0015] Catheter 9 is connected to a conduit 90, which is fitted with and acted on downstream by a blood pump 3; a gauge 20 is also provided to measure the intake arterial pressure of the patient. The successive portions of the path along which the blood flows are defined by conduit portions 91, 92, 93, 94 and 95.
  • [0016] Pump 3 pumps the blood downstream (in the direction shown by the arrows) to a connecting member 4, after first adding heparin by means of a conduit 50 connected to conduit 91 and to a heparin tank (syringe) 5. A conduit 60 is connected to the input of connecting member 4 to supply, by means of a pump 61, a refill liquid or infusion contained in a tank 6 and heated by heating means 62.
  • A [0017] gauge 40 is provided at connecting member 4 to measure the pressure at that point along the path.
  • Downstream from connecting [0018] member 4, conduit portion 92 is connected to an oxygenating device 7 or “decapneisator”, which may be a Jostra Polystan mycro or Jostra Safe mycro neonatal type, and which is connected by a conduit 77 to an oxygen tank 78, and is fitted inside with an oxygenating membrane 71. Oxygenating device 7 provides for supplying oxygen to eliminate CO2 from the blood; for which purpose, CO2 is eliminated through an outlet 70 of device 7 and sent to measuring means not shown.
  • Downstream from “decapneisator” [0019] 7, conduit portion 93 is connected to a blood filter or haemofilter 8 having an output connected to a conduit 80 for discharging ultrafiltrate into a collecting tank 81. Conduit 80 is fitted with control means 82, which may be defined, for example, by a detector for detecting blood loss in the ultrafiltrate, and which acts directly on conduit 80.
  • [0020] Blood filter 8 may be a currently marketed type, such as a MEDICA company MEDISULFONE D200 haemofilter.
  • [0021] Apparatus 1 according to the present invention advantageously does not employ an ultrafiltrate pump, in that, using oxygenating device 7, ultrafiltration takes place naturally, in a more physiologically correct manner.
  • Downstream from [0022] filter 8, conduit portion 94 is connected to a member 49 defined by a venous vessel and having a gauge 48 for measuring the pressure of the return blood to the patient.
  • Downstream from [0023] member 49, conduit portion 95—which is fitted with an air detector 47 to prevent emboli (e.g. a UABD ultrasonic air bubble detector)—is connected to a return catheter 9′ for feeding the blood back to patient P.
  • In other words, an apparatus in accordance with the present invention comprises a CRRT machine, and an oxygenating device or “decapneisator”. By way of example, the CRRT machine may be an Equasmart Medica equipped with appropriate connecting tubes, catheters, connections, etc. [0024]
  • Testing has revealed numerous advantages. [0025]
  • In particular, the apparatus is advantageous in all cases in which the oxygen concentration of the blood requires supplementing, and especially in eliminating CO[0026] 2 in patients in which correct substitute respiration therapy is difficult to apply.
  • In actual use, the apparatus is connected to the patient undergoing CVVH treatment, and a patient weight loss is set as required. For example, a total weight loss of 2400 g and an hourly loss of 100 g may be programmed. These two parameters determine a treatment time of 24 hours. Administration of an anticoagulant equal to 1.5 times the blood coagulation time may be set; in which case, a pump flow rate (QB) of 280-300 ml/min and an oxygen flow rate (QO[0027] 2) of 500 ml/min will be programmed.
  • At therapy method level, with the present invention, the patient is connected to a CRRT machine, using an oxygenating device located and acting upstream from the blood filter and downstream from the blood pump. This location of the oxygenating device is particularly important. In fact, it means the oxygenating membranes of the oxygenating device operate without the intake (negative) pressure along the portion upstream from the blood pump, and also without the blood concentration characteristic of the venous portion, which could eventually impair their efficiency. [0028]
  • Again at therapy level, a weight loss (i.e. the quantity of liquid to be drained) may be set as required in each specific case, i.e. as prescribed by the physician. An anticoagulant infusion in line with standard CRRT protocols will therefore be provided, with a blood flow rate (QB) of over 300 ml/min, and an oxygen flow rate (QO[0029] 2) higher than QB. It is important to continuously monitor both coagulation time, which must be kept constantly at one and a half times normal, and oxygen saturation, haematocrit, blood volume values, etc. For this purpose, a CRITE-LINE or similar apparatus may be used.
  • Clearly, changes may be made to the form, dimensions, component part locations, and type of materials employed in the embodiment described and illustrated herein without, however, departing from the scope of the present invention. [0030]

Claims (5)

1) An apparatus for CRRT therapy of the type performable using a haemofiltration machine, comprising connecting means (9, 9′) from and to respective blood vessels of a patient, blood processing means comprising a pump (3), means for adding drugs or other therapeutic substances (5), means for feeding refill liquid into the blood (6), and blood filtration means (8), cascade-connected to one another by relative conduits; characterized by comprising an oxygenating device (7).
2) An apparatus as claimed in claim 1, characterized in that said oxygenating device (7) is located downstream from blood processing means comprising a blood pump (3).
3) An apparatus as claimed in claim 1, characterized in that said oxygenating device (7) is located upstream from the blood filtration means (8).
4) An apparatus as claimed in claim 1, characterized in that said oxygenating device (7) is located upstream from the blood filtration means (8) and downstream from blood processing means comprising a blood pump (3).
5) An apparatus as claimed in claim 1, characterized in that said oxygenating device (7) comprises an oxygenating membrane (71), is connected to an oxygen tank (78), and has an outlet (70) through which carbon dioxide is eliminated.
US10/699,098 2002-10-31 2003-10-30 Apparatus usable in haemofiltration treatment Abandoned US20040143207A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/043,696 US7942842B2 (en) 2002-10-31 2008-03-06 Apparatus and method for the treatment of blood

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000208A ITFI20020208A1 (en) 2002-10-31 2002-10-31 EQUIPMENT USED IN HEMOFILTRATION TREATMENTS.
ITFI2002A000208 2002-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/043,696 Continuation US7942842B2 (en) 2002-10-31 2008-03-06 Apparatus and method for the treatment of blood

Publications (1)

Publication Number Publication Date
US20040143207A1 true US20040143207A1 (en) 2004-07-22

Family

ID=32088997

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/699,098 Abandoned US20040143207A1 (en) 2002-10-31 2003-10-30 Apparatus usable in haemofiltration treatment
US12/043,696 Active 2024-10-20 US7942842B2 (en) 2002-10-31 2008-03-06 Apparatus and method for the treatment of blood

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/043,696 Active 2024-10-20 US7942842B2 (en) 2002-10-31 2008-03-06 Apparatus and method for the treatment of blood

Country Status (6)

Country Link
US (2) US20040143207A1 (en)
EP (1) EP1415673B2 (en)
AT (1) ATE457757T2 (en)
DE (1) DE60331281D1 (en)
ES (1) ES2341324T5 (en)
IT (1) ITFI20020208A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080243045A1 (en) * 2003-10-03 2008-10-02 Medical Service S.R.L Apparatus and method for the treatment of blood
EP2606921A1 (en) 2011-12-21 2013-06-26 Infomed SA Device for purifying blood by extracorporeal circulation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20030256A1 (en) * 2003-10-09 2005-04-10 Angela Caramuta DEVICE FOR THE ELIMINATION OF CARBON DIOXIDE
US8105491B2 (en) * 2004-04-27 2012-01-31 Vital Therapies, Inc. Metabolic detoxification and method
EP2238995A1 (en) * 2009-04-09 2010-10-13 Gazzano, Michele System for the treatment of blood
ITBO20120197A1 (en) * 2012-04-12 2013-10-13 Medical Service S R L EQUIPMENT USED IN MECHANICAL OR ASSISTED VENTILATION PROCEDURES
CN104971391A (en) * 2015-06-19 2015-10-14 南方医科大学珠江医院 Novel combined type liver and kidney support system CRRT mode tube
ITUB20159161A1 (en) * 2015-12-18 2017-06-18 Eurosets Srl EQUIPMENT FOR BLOOD DECAPNIZATION
ITUB20159389A1 (en) 2015-12-18 2017-06-18 Eurosets Srl EQUIPMENT FOR BLOOD DECAPNIZATION
IT201700038389A1 (en) * 2017-04-07 2018-10-07 In10Sivecare S R L Equipment for extracorporeal blood treatment
DE102021109242A1 (en) 2021-04-13 2022-10-13 B.Braun Avitum Ag Extracorporeal circuit for decapneization of organic fluids

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828543A (en) * 1986-04-03 1989-05-09 Weiss Paul I Extracorporeal circulation apparatus
US5858238A (en) * 1996-03-08 1999-01-12 Baxter Research Medical, Inc. Salvage of autologous blood via selective membrane/sorption technologies
US20020077581A1 (en) * 2000-12-19 2002-06-20 Alan Davidner Simplified cerebral retroperfusion apparatus and method
US6561997B1 (en) * 1999-04-23 2003-05-13 The Regents Of The University Of Michigan Extracorporeal fluid circuit and related methods
US6626857B1 (en) * 1998-11-19 2003-09-30 Tomio Ohta Extracorporeal circulation device and method for isolation temperature control method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666425A (en) * 1985-12-17 1987-05-19 The Dis Corporation Device for perfusing an animal head
DE4113185C1 (en) * 1991-04-23 1992-07-23 Fresenius Ag, 6380 Bad Homburg, De Extracorporeal blood gas exchanger - has gas exchanger with blood inlet and outlet lines coupled by ultra-filtrate discharge device
US5211849B1 (en) * 1991-10-11 1997-05-27 Childrens Hosp Medical Center Hemofiltration system and method
US5368555A (en) * 1992-12-29 1994-11-29 Hepatix, Inc. Organ support system
US6193681B1 (en) * 1998-09-14 2001-02-27 American Immuno Tech, Llc. Septicemia prevention and treatment system
DE19858950A1 (en) * 1998-12-09 2000-06-29 Robby Knueppel Device for extra-corporal exchange of gas and substances in blood, comprises two exchange chambers with semi-permeable membranes
JP2001178817A (en) * 1999-12-24 2001-07-03 Terumo Corp Device for artificial kidney, quality evaluating device using the same and fluid circuit
CN100346869C (en) * 2001-02-07 2007-11-07 尼弗茹斯公司 Method and apparatus for hemodiafiltration delivery module

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828543A (en) * 1986-04-03 1989-05-09 Weiss Paul I Extracorporeal circulation apparatus
US5858238A (en) * 1996-03-08 1999-01-12 Baxter Research Medical, Inc. Salvage of autologous blood via selective membrane/sorption technologies
US6626857B1 (en) * 1998-11-19 2003-09-30 Tomio Ohta Extracorporeal circulation device and method for isolation temperature control method
US6561997B1 (en) * 1999-04-23 2003-05-13 The Regents Of The University Of Michigan Extracorporeal fluid circuit and related methods
US20020077581A1 (en) * 2000-12-19 2002-06-20 Alan Davidner Simplified cerebral retroperfusion apparatus and method

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080243045A1 (en) * 2003-10-03 2008-10-02 Medical Service S.R.L Apparatus and method for the treatment of blood
US8070952B2 (en) 2003-10-03 2011-12-06 Medical Service S.R.L. Apparatus and method for the treatment of blood
EP2606921A1 (en) 2011-12-21 2013-06-26 Infomed SA Device for purifying blood by extracorporeal circulation

Also Published As

Publication number Publication date
EP1415673B1 (en) 2010-02-17
ES2341324T5 (en) 2018-10-24
EP1415673A1 (en) 2004-05-06
US20080154171A1 (en) 2008-06-26
ATE457757T2 (en) 2010-03-15
US7942842B2 (en) 2011-05-17
ES2341324T3 (en) 2010-06-18
EP1415673B2 (en) 2018-06-20
ITFI20020208A1 (en) 2004-05-01
DE60331281D1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
US7942842B2 (en) Apparatus and method for the treatment of blood
DK2324871T3 (en) Citratantikoaguleringssystem for extracorporeal blood treatments
US10172994B2 (en) Hemodiafiltration method
US9440018B2 (en) Method for ultrafiltration of blood
EP0951303B1 (en) Device for preparation of substitution solution
EP1590017B1 (en) Extracorporeal blood treatment machine.
JP2001511679A (en) Blood filtration system
MXPA06006835A (en) Medical fluid therapy flow control systems and methods.
US7314554B2 (en) Extracorporeal blood treatment machine
Ronco et al. Current technology for continuous renal replacement therapies
US10821216B1 (en) Method and apparatus for a hemodiafiltration module for use with a dialysis machine
WO2005075007A1 (en) Device and apparatus for the elimination of the carbon dioxide from the blood
US20230372594A1 (en) Single lumen hybrid connection to legacy system
Ronco et al. The evolving technology for continuous renal replacement therapy from current standards to high-volume hemofiltration
WO2021059817A1 (en) Blood purification device
EP4323033A1 (en) Extracorporeal circuit for decapneization of organic fluids
Capodicasa et al. CAPD+ Hemoperfusion once a week for end stage renal disease
Ronco et al. Technical requirements for high volume hemofiltration

Legal Events

Date Code Title Description
AS Assignment

Owner name: FREEVIEW VENTURES LLC, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DELLA TORRE, FLORENZIANO;REEL/FRAME:015176/0502

Effective date: 20040219

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION